Telisotuzumab vedotin is a c-Met-directed antibody-drug conjugate (ADC) consisting of the humanized recombinant IgG1κ monoclonal antibody telisotuzumab linked to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE) through a protease-cleavable valine-citrulline (vc) linker. The ADC has an average drug-to-antibody ratio (DAR) of approximately 3.
The U.S. FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) on May 14, 2025, for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, defined as at least 50% of tumor cells showing strong 3+ staining by an FDA-approved test, following prior systemic therapy.
Telisotuzumab vedotin is a biological ADC rather than a conventional small-molecule API. FDA's Global Substance Registration System identifies it under CAS No. 1714088-51-3 and UNII 976X9VXC3Z. Its development and synonym identifiers include ABBV-399, ABT-399, ABT-700-VCMMAE, and PR-1420682.
The FDA describes telisotuzumab vedotin as having an approximate molecular weight of 152 kDa. Each antibody molecule carries an average of approximately three MMAE molecules.
Telisotuzumab vedotin combines three principal structural components:
The conjugate is designed to recognize c-Met on tumor cells, undergo receptor-mediated internalization and release MMAE following intracellular proteolytic cleavage of the linker.
Telisotuzumab vedotin binds to c-Met, the receptor tyrosine kinase encoded by the MET proto-oncogene. After binding, the ADC is internalized into the tumor cell and transported to the lysosome. Proteolytic cleavage of the vc linker releases MMAE, which inhibits microtubule function and ultimately causes cell-cycle arrest and apoptotic cell death.
The antibody component also blocks c-Met signaling by interacting with the receptor, providing an additional mechanism associated with the anti-tumor activity of the ADC.
Telisotuzumab vedotin is an oncology biologic used for c-Met-overexpressing non-squamous NSCLC.
The FDA-approved population consists of adults with:
An FDA-approved companion diagnostic, the VENTANA MET (SP44) RxDx Assay, is used to identify patients with high c-Met protein overexpression who may be eligible for treatment.
Because telisotuzumab vedotin is an ADC, its quality-control strategy differs substantially from conventional small-molecule APIs. Relevant critical quality attributes include:
FDA's chemistry review identifies the product as a large-molecule ADC and describes the drug product as a lyophilized powder supplied in single-dose vials.
Telisotuzumab vedotin is manufactured as a biological ADC through production and purification of the recombinant antibody followed by controlled conjugation to the MMAE-containing linker-payload. The manufacturing strategy must maintain control over antibody quality, conjugation efficiency, DAR distribution, aggregates, free payload and biological activity.
Because the ADC is structurally heterogeneous by nature, DAR and product-related variants are particularly important quality attributes. FDA reports an average DAR of approximately 3.
FDA confirms the approximate 152 kDa molecular weight, average DAR of 3 and 20 mg/100 mg vial presentations.
The approved drug product is supplied as a lyophilized powder in single-dose vials. FDA identifies 20 mg/vial and 100 mg/vial presentations. Following reconstitution, the solution has a target pH of approximately 6.0.
API/drug-substance storage should follow validated stability data and the applicable registered manufacturing specification rather than being inferred from the finished-product presentation.
Pharmaceutical-grade Telisotuzumab Vedotin documentation may include:
Telisotuzumab vedotin is a complex c-Met-targeted ADC requiring specialized biologics and conjugation capabilities. A suitable manufacturing and quality program should control the antibody component, linker-payload conjugation, DAR distribution, aggregates, free MMAE, product-related variants and biological potency.
For pharmaceutical development and commercial requirements, Telisotuzumab Vedotin should therefore be handled as an ADC biological drug substance, rather than applying conventional small-molecule API specifications such as residue on ignition, melting point or specific rotation.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |